Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?
Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.
BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial
A next-generation cancer immunotherapy by BioNTech and partner Bristol Myers Squibb led to encouraging tumour shrinkage in a mid-stage trial on small cell lung cancer that has started spreading, the German biotech firm said on Monday.
Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology Leadership
Bristol-Myers Squibb is a Strong Buy at current levels, with a $54 price target and attractive 5.2% dividend yield. The company's innovative growth portfolio is gaining traction, offsetting legacy declines and positioning BMY for a turnaround. Valuation is compelling: BMY trades at a deep discount to peers, with limited downside and strong profitability metrics.
7 Big Yields From The Beat-Up Healthcare Sector
Healthcare stocks haven't moved since the April lows. As contrarian investors, this neglect piques our interest.
BMY vs GSK: Which Biopharma Bigwig Has Better Prospects for Now?
Bristol Myers leans on new launches to offset legacy drug declines, while GSK's diverse portfolio and strong HIV lineup keep growth on track.
5 Strong-Buy Stocks With Hard-to-Find 5% and Higher Yields
Dividend stocks are a favorite among investors for good reason. They provide a steady income stream and offer a promising avenue for total return.
Does Cobenfy Have the Potential to Become a Top Drug for BMY?
Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline expansion potential.
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?
Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.
BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?
BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We recommend investors to stay on the sidelines for now.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity
Bristol Myers Squibb is trading at a generational bargain, near 7x earnings, with a compelling 5.6% dividend yield and strong cash flow. Recent Q2 results beat expectations, and management is focused on growth initiatives, including AI-driven drug discovery and new partnerships. Despite near-term earnings declines, due to patent expirations, AI and pipeline opportunities offer potential upside not priced into the stock.
